The US Food and Drug Administration issued draft guidance endorsing measurable residual disease (MRD) and complete response as potential endpoints to support accelerated approval pathways in multiple myeloma. The agency’s move follows internal advisory recommendations and aims to reduce development timelines for therapies that clear tumor cells to deep levels. Regulators and sponsors will need to define MRD assay standards and contextualize clinical benefit; MRD refers to sensitive molecular or cellular tests that detect residual malignant cells below conventional imaging thresholds.